Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
German Version of the Telehealth Usability Questionnaire and Derived Short Questionnaires for Usability and Perceived Usefulness in Health Care Assessment in Telehealth and Digital Therapeutics: Instrument Validation Study.
Zimmermann J, Morf H, Scharf F, Knitza J, Moeller H, Muehlensiepen F, Nathrath M, Orlemann T, Voelker T, Deckers M. Zimmermann J, et al. Among authors: nathrath m. JMIR Hum Factors. 2024 Nov 21;11:e57771. doi: 10.2196/57771. JMIR Hum Factors. 2024. PMID: 39571151 Free PMC article.
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.
Hägele P, Staus P, Scheible R, Uhlmann A, Heeg M, Klemann C, Maccari ME, Ritterbusch H, Armstrong M, Cutcutache I, Elliott KS, von Bernuth H, Leahy TR, Leyh J, Holzinger D, Lehmberg K, Svec P, Masjosthusmann K, Hambleton S, Jakob M, Sparber-Sauer M, Kager L, Puzik A, Wolkewitz M, Lorenz MR, Schwarz K, Speckmann C, Rensing-Ehl A, Ehl S; ALPID study group. Hägele P, et al. Lancet Haematol. 2024 Feb;11(2):e114-e126. doi: 10.1016/S2352-3026(23)00362-9. Lancet Haematol. 2024. PMID: 38302222
Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS).
Bielack SS, Mettmann V, Hecker-Nolting S, Borkhardt A, Hardes J, Kager L, von Kalle T, Kevric M, Koscielniak E, Kratz CP, Kühne T, Nathrath M, Rossig C, Sorg B, Sparber-Sauer M, Werner M, Blattmann C. Bielack SS, et al. Among authors: nathrath m. Pediatr Blood Cancer. 2024 Dec;71(12):e31344. doi: 10.1002/pbc.31344. Epub 2024 Sep 29. Pediatr Blood Cancer. 2024. PMID: 39344062
The German sickle cell disease registry reveals a surprising risk of acute splenic sequestration and an increased transfusion requirement in patients with compound heterozygous sickle cell disease HbS/β-thalassaemia and no or low HbA expression.
Allard P, Tagliaferri L, Weru V, Cario H, Lobitz S, Grosse R, Bleeke M, Oevermann L, Hakimeh D, Jarisch A, Kopp-Schneider A, Kulozik AE, Kunz JB; German Sickle Cell Disease Study Group; Lassay L. Allard P, et al. Eur J Haematol. 2024 Oct;113(4):501-509. doi: 10.1111/ejh.14259. Epub 2024 Jun 30. Eur J Haematol. 2024. PMID: 38946051
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin KM, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Tröger A, Koller M, Menhart K, Riemenschneider MJ, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdörfer P, Kühnle I, Dilloo D, Schönberger S, Schwabe G, von Luettichau I, Graf N, Schlegel PG, Frühwald M, Jorch N, Paulussen M, Schneider DT, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Fröhlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, Foell J. Corbacioglu S, et al. Among authors: nathrath m. Lancet Oncol. 2024 Jul;25(7):922-932. doi: 10.1016/S1470-2045(24)00202-X. Lancet Oncol. 2024. PMID: 38936379 Free article. Clinical Trial.
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.
Green D, van Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D, Bielack SS, Botchu R, Boye K, Brennan B, Capra M, Cottone L, Dirksen U, Fagioli F, Fernandez N, Flanagan AM, Gambarotti M, Gaspar N, Gelderblom H, Gerrand C, Gomez-Mascard A, Hardes J, Hecker-Nolting S, Kabickova E, Kager L, Kanerva J, Kester LA, Kuijjer ML, Laurence V, Lervat C, Marchais A, Marec-Berard P, Mendes C, Merks JHM, Ory B, Palmerini E, Pantziarka P, Papakonstantinou E, Piperno-Neumann S, Raciborska A, Roundhill EA, Rutkauskaite V, Safwat A, Scotlandi K, Staals EL, Strauss SJ, Surdez D, Sys GML, Tabone MD, Toulmonde M, Valverde C, van de Sande MAJ, Wörtler K, Campbell-Hewson Q, McCabe MG, Nathrath M. Green D, et al. Among authors: nathrath m. Clin Cancer Res. 2024 Aug 15;30(16):3395-3406. doi: 10.1158/1078-0432.CCR-24-0101. Clin Cancer Res. 2024. PMID: 38869831 Free PMC article. Review.
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma.
Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE. Zhou Y, et al. Among authors: nathrath m. Nat Commun. 2024 Apr 1;15(1):2810. doi: 10.1038/s41467-024-47031-y. Nat Commun. 2024. PMID: 38561347 Free PMC article.
Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group.
Mettmann VL, Blattmann C, Friedel G, Harrabi S, von Kalle T, Kager L, Kevric M, Kühne T, Nathrath M, Sorg B, Werner M, Bielack SS, Hecker-Nolting S. Mettmann VL, et al. Among authors: nathrath m. Cancers (Basel). 2024 Jan 8;16(2):275. doi: 10.3390/cancers16020275. Cancers (Basel). 2024. PMID: 38254767 Free PMC article.
Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH, Difilippo V, Kovac M, Cornmark L, Magnusson L, Nilsson J, van den Bos H, Spierings DC, Bidgoli M, Jonson T, Sumathi VP, Brosjö O, Staaf J, Foijer F, Styring E, Nathrath M, Baumhoer D, Nord KH. Saba KH, et al. Among authors: nathrath m. J Pathol. 2024 Feb;262(2):147-160. doi: 10.1002/path.6219. Epub 2023 Nov 27. J Pathol. 2024. PMID: 38010733
103 results